Objective
emesis, nausea
NASOPHARYNGEAL CARCINOMA
To compare the efficacy and safety of fosaprepitant weekly vs every 3 weeks for the prevention of nausea and emesis caused by CCRT among patients with nasopharyngeal carcinoma.